Standard Dosing Schedule for Xgeva
Xgeva (denosumab) is injected subcutaneously once every 4 weeks (about every 28 days) to prevent bone complications in adults with bone metastases from solid tumors, multiple myeloma, or osteoporosis-related fractures in high-risk postmenopausal women.[1] This schedule supports bone health by inhibiting osteoclast activity, reducing skeletal-related events like fractures.
How Long Do You Stay on Xgeva?
Treatment continues indefinitely as long as benefits outweigh risks, often for years in cancer patients or until osteoporosis risk decreases. Doctors adjust based on bone density scans, calcium levels, and side effects; no fixed endpoint exists.[1][2]
What If I Miss a Dose?
Administer the missed dose as soon as possible, then resume the every-4-weeks schedule. If it's nearly time for the next dose, skip the missed one—do not double up.[1]
Differences from Prolia for Bone Health
Xgeva and Prolia both use denosumab but differ in approved uses and dosing context:
| Aspect | Xgeva | Prolia |
|--------|-------|--------|
| Primary Use | Cancer-related bone metastases | Osteoporosis in non-cancer patients |
| Dose Strength | 120 mg | 60 mg |
| Frequency | Every 4 weeks | Every 6 months |
| Setting | Often oncologist-administered | Self- or clinic-administered |
Prolia's less frequent schedule suits general bone health without cancer.[1][2]
Common Side Effects and Monitoring
Patients report low calcium (hypocalclycemia), jaw bone issues (osteonecrosis), and thigh fractures. Get blood tests before starting and regularly; take calcium/vitamin D supplements. Jaw pain or slow-healing mouth issues require immediate dental checks.[1]
Cost and Access for Bone Health
A single Xgeva dose costs $2,000–$3,000 without insurance; programs like Amgen SupportPlus offer copay help down to $5/month for eligible patients. Check patents—no generic yet, with key U.S. patents expiring around 2025–2030. DrugPatentWatch.com.[3]
Sources:
[1] Xgeva Prescribing Information, Amgen. Link
[2] FDA Label for Xgeva. Link
[3] DrugPatentWatch.com. Link